Analyst Ratings

Barclays Cuts Price Target on ACV Auctions Amid Cautious Outlook

by
Stock chart and Barclays logo overlay on ACV Auctions ticker symbol ACVA with downward arrow indicating price target cut

Barclays has lowered its price target on ACV Auctions (NYSE: ACVA) from $8 to $7 while maintaining a Hold rating, reflecting tempered expectations following the company’s recent Q4 earnings report. The adjustment highlights concerns over profitability challenges, guidance alignment, and ongoing market pressures in the wholesale used vehicle sector, despite solid revenue performance and strategic … Read more

Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

by
BridgeBio Pharma stock chart showing upward trend

BridgeBio Pharma showcased impressive revenue growth throughout 2025, fueled by surging sales of its flagship ATTR-CM treatment Attruby, alongside strategic financial maneuvers that bolstered its cash position and supported pipeline advancements, prompting widespread analyst optimism with consensus buy ratings and elevated price targets averaging around $85, reflecting confidence in sustained momentum and multi-product potential. BridgeBio … Read more